Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday. 

Pfizer said the Phase 3 clinical trial began in late July 2020 and completed enrollment of 46,331 participants in January, including over 2,200 participants aged 12-15. The company also plans to study the vaccine in pregnant women, among other populations. 

Vaccines from Pfizer and Moderna Inc. are not currently available for use in children due to a lack of studies. The Food and Drug Administration last month authorized emergency use of the vaccine for individuals age 16 and older. 

Related News Articles

Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen,…
Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…
Headline
The Centers for Medicare & Medicaid Services Friday released updated guidance on COVID-19 vaccination coverage and reimbursement to help Medicaid, Children…
Headline
The Food and Drug Administration yesterday revised its emergency use authorization for the Johnson & Johnson COVID-19 vaccine to limit its use to…